日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Novel nutraceutical combination restores hepatic deiodinase expression and protein levels under inflammatory conditions: evidence from an in vitro model

新型营养保健品组合可在炎症条件下恢复肝脏脱碘酶的表达和蛋白水平:来自体外模型的证据

Valeri, E; Loupakis, F; Pasqualetti, G; Paccosi, E; Proietti De Santis, L; Filippi, S

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

在BRAF V600E突变转移性结直肠癌患者中,接受恩考非尼联合西妥昔单抗治疗(伴或不伴比美替尼治疗)的生活质量:来自BEACON CRC研究的患者报告结局

Kopetz, S; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Loupakis, F; Hong, Y S; Steeghs, N; Guren, T K; Arkenau, H-T; Garcia-Alfonso, P; Belani, A; Zhang, X; Tabernero, J

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas

BRAF突变型转移性结直肠腺癌的肿瘤内形态学和转录组异质性

Angerilli, V; Fontana, E; Lonardi, S; Sbaraglia, M; Borelli, B; Munari, G; Salmaso, R; Guzzardo, V; Spolverato, G; Pucciarelli, S; Pilati, P; Hahne, J C; Bergamo, F; Zagonel, V; Dei Tos, A P; Sadanandam, A; Loupakis, F; Valeri, N; Fassan, M

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

MAPK信号通路基因变异对接受一线FOLFIRI联合贝伐单抗治疗的转移性结直肠癌患者预后的影响:来自FIRE-3和TRIBE试验的数据

Berger, M D; Stintzing, S; Heinemann, V; Yang, D; Cao, S; Sunakawa, Y; Ning, Y; Matsusaka, S; Okazaki, S; Miyamoto, Y; Suenaga, M; Schirripa, M; Soni, S; Zhang, W; Falcone, A; Loupakis, F; Lenz, H-J

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

DNA修复相关基因的遗传变异可预测TAS-102治疗难治性转移性结直肠癌患者的疗效

Suenaga, M; Schirripa, M; Cao, S; Zhang, W; Yang, D; Murgioni, S; Rossini, D; Marmorino, F; Mennitto, A; Ning, Y; Okazaki, S; Berger, M D; Miyamoto, Y; Gopez, R Jr; Barzi, A; Yamaguchi, T; Loupakis, F; Lenz, H-J

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

CXCR4多态性可预测接受一线贝伐单抗化疗的转移性结直肠癌患者的无进展生存期

Matsusaka, S; Cao, S; Hanna, D L; Sunakawa, Y; Ueno, M; Mizunuma, N; Zhang, W; Yang, D; Ning, Y; Stintzing, S; Sebio, A; Stremitzer, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, M D; El-Khoueiry, R; Mendez, A; Ichikawa, W; Loupakis, F; Lenz, H-J

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials

肿瘤相关巨噬细胞 (TAM) 调控基因的变异可预测转移性结直肠癌患者接受贝伐单抗治疗的疗效:TRIBE 和 FIRE3 试验的结果

Sunakawa, Y; Stintzing, S; Cao, S; Heinemann, V; Cremolini, C; Falcone, A; Yang, D; Zhang, W; Ning, Y; Stremitzer, S; Matsusaka, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, M D; Graver, S; Mendez, A; Scherer, S J; Loupakis, F; Lenz, H-J

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

BRAF和RAS突变作为转移性结直肠癌肝切除术患者的预后因素

Schirripa, M; Bergamo, F; Cremolini, C; Casagrande, M; Lonardi, S; Aprile, G; Yang, D; Marmorino, F; Pasquini, G; Sensi, E; Lupi, C; De Maglio, G; Borrelli, N; Pizzolitto, S; Fasola, G; Bertorelle, R; Rugge, M; Fontanini, G; Zagonel, V; Loupakis, F; Falcone, A

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

对接受 FOLFOXIRI 联合贝伐单抗治疗的结直肠癌患者进行肝转移的组织病理学评估

Loupakis, F; Schirripa, M; Caparello, C; Funel, N; Pollina, L; Vasile, E; Cremolini, C; Salvatore, L; Morvillo, M; Antoniotti, C; Marmorino, F; Masi, G; Falcone, A

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

转移性结直肠癌患者节拍式伊立替康的药代动力学和药效学研究

Allegrini G, Falcone A, Fioravanti A, Barletta M T, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel R S, Danesi R, Del Tacca M, Bocci G